The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Aurobindo Pharma USA Inc. has initiated a Drug Recall at the Retail Level for the product **Quinapril and Hydrochlorothiazide Tablets USP 20 mg / 12.5 mg; Batch Number(s) QE2021005-A** and **QE2021010-A** (90's count HDPE bottle) from USA market due to presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N Nitroso-Quinapril above the proposed interim limit.

Aurobindo Pharma USA Inc. began shipping of these batches (QE2021005-A and QE2021010-A) to customers nationwide **May 2021** through **June 2021.**